Theralase Technologies Inc (TLTFF)

[123414]

REB approval had a deadline of beginning of Q2. The guidance for enrollment and treatment ...

Health Canada Clinical Trial Authorization (“CTA”)Complete, Investigational Testing Authorization (“ITA”)Complete. Clinical Site Review Ethics Board (“REB”)Pending- Approval to Commence Enrolling and Treating Patients in Canada 2Q2019 Completed!!!
Theralase Commences Phase II NMIBC Clinical Study

FDA Investigational New Drug (“IND”) and European IND Approval to Commence Enrolling and Treating Patients in the United States and Europe 3Q2019

Enroll, Treat and Follow-Up Approximately 100 NMIBC Patients in Canada, the United States and Europe 2Q2019 to 4Q2021


http://theralase.com/wp-content/uploads/2019/03/Theralase-Corporate-Power-Point-Presentation-03-25-2019.pdf
___________________
The Company is focusing on opening Canadian, US and international study sites throughout Q2 2019 and Q1 2020 with the PIs that attended the 5th annual MSAB meeting

Dr. Shawn Shirazi, CEO-Drug Division, Theralase stated, "Theralase stakeholders should be excited about the ability of the Company to execute on its strategic objectives


Theralase’s 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
May 13, 2019
___________________
Kinda looks like they intend to have all the Canadian sites open. Perhaps everything lined up for all Canadian sites by end of Q2. And have at least began enrollment and treatments in Q2 as well.